Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

19
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
19
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

18
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
18
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

21
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
21
Hepatic Portal System01:21

Hepatic Portal System

2.9K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
2.9K
Nursing Ethical Principles II01:27

Nursing Ethical Principles II

1.4K
Ethical principles are essential in guiding nurses to fulfill their responsibilities, focusing on the quality of nursing care and decision-making. These principles, including autonomy, beneficence, non-maleficence, justice, and fidelity, shape the ethical framework within healthcare settings.
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A conceptual health economic modelling framework to assess the cost-effectiveness of molecular target-driven treatment regimens in oncology.

Acta oncologica (Stockholm, Sweden)·2026
Same author

The Economic Burden of Alopecia Areata: Evidence from a Survey in Norway and Sweden.

Acta dermato-venereologica·2026
Same author

Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities.

Molecular oncology·2025
Same author

Correlations between the prescribing patterns of psychotropic medications and socio-economic factors during the COVID-19 pandemic: A cross-sectional Swedish registry study.

PloS one·2025
Same author

Strategies to reduce the cancer burden and improve access to effective and affordable cancer interventions in Europe.

Molecular oncology·2025
Same author

Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Sweden.

Blood pressure·2025

Related Experiment Video

Updated: Oct 11, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.3K

Value appropriation in hepatitis C.

Peter Lindgren1,2, Sofia Löfvendahl3, Gunnar Brådvik3

  • 1Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, 171 77, Stockholm, Sweden. peter.lindgren@ki.se.

The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|December 2, 2021
PubMed
Summary
This summary is machine-generated.

Sweden

Keywords:
Consumer surplusCost-effectivenessHepatitis CPharmaceutical reimbursementProducer surplus

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

11.6K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.9K

Related Experiment Videos

Last Updated: Oct 11, 2025

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.3K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

11.6K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.9K

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Public Health Policy

Background:

  • Swedish government allocated €150 million for hepatitis C drugs in 2015.
  • Introduction of direct-acting antivirals (DAAs) offered higher cure rates and fewer side effects.
  • DAAs presented cost-effectiveness but significant budget impact challenges.

Purpose of the Study:

  • To estimate the social surplus generated by new direct-acting antivirals (DAAs) for hepatitis C in Stockholm, Sweden.
  • To analyze the economic impact of DAAs from 2014-2019.
  • To evaluate the role of government funding in the adoption of innovative treatments.

Main Methods:

  • Social surplus estimation using registry data for drug use and costs.
  • Markov modeling to assess future healthcare costs and Quality-Adjusted Life Year (QALY) gains.
  • Comparison with previous interferon-based therapies as a counterfactual.

Main Results:

  • Substantial social surplus was generated, with producers initially capturing 15% of it.
  • Consumer surplus primarily derived from QALY gains and reduced indirect costs.
  • QALY gains grew slower than patient numbers as eligibility criteria expanded.

Conclusions:

  • Government funding facilitated significant surplus for consumers and producers.
  • Reduced indirect costs played a crucial role in the overall economic benefit.
  • The funding model offers a potential blueprint for financing future innovative therapies.